Moomoo AI 已提取核心信息
On February 28, 2024, Tonix Pharmaceuticals Holding Corp. announced the successful completion of the clinical stage of its Phase 1 trial for TNX-1500, a potential treatment for organ transplant rejection and autoimmune diseases. The trial involved a single ascending dose escalation study of TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody, in healthy volunteers. Results from the trial are anticipated in the third quarter of 2024. The company's CEO, Seth Lederman, highlighted the potential of TNX-1500 to improve transplant tolerance and reduce the risk of thrombosis associated with first-generation anti-CD40L mAbs. Tonix Pharmaceuticals, which focuses on developing therapeutics for central nervous system disorders and immunology, is also planning a Phase 2 trial for kidney transplant rejection prevention. The company aims to submit a New Drug Application for another candidate, Tonmya, for the management of fibromyalgia in the second half of 2024.
On February 28, 2024, Tonix Pharmaceuticals Holding Corp. announced the successful completion of the clinical stage of its Phase 1 trial for TNX-1500, a potential treatment for organ transplant rejection and autoimmune diseases. The trial involved a single ascending dose escalation study of TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody, in healthy volunteers. Results from the trial are anticipated in the third quarter of 2024. The company's CEO, Seth Lederman, highlighted the potential of TNX-1500 to improve transplant tolerance and reduce the risk of thrombosis associated with first-generation anti-CD40L mAbs. Tonix Pharmaceuticals, which focuses on developing therapeutics for central nervous system disorders and immunology, is also planning a Phase 2 trial for kidney transplant rejection prevention. The company aims to submit a New Drug Application for another candidate, Tonmya, for the management of fibromyalgia in the second half of 2024.
2024年2月28日，Tonix Pharmicals Holding Corp. 宣布成功完成其 TNX-1500 的1期临床阶段，该试验是器官移植排斥反应和自身免疫性疾病的潜在治疗方法。该试验涉及在健康志愿者中对一种 FC 修饰的人源化抗 CD40L 单克隆抗体 TNX-1500 的单一剂量递增研究。该试验的结果预计将在2024年第三季度公布。该公司首席执行官塞思·莱德曼强调了 TNX-1500 有可能提高移植耐受性，降低与第一代抗CD40L单克隆抗体相关的血栓形成风险。专注于开发中枢神经系统疾病和免疫学疗法的Tonix Pharmicals还计划进行一项预防肾脏移植排斥反应的2期试验。该公司的目标是在2024年下半年提交另一候选药物Tonmya的新药申请，用于治疗纤维肌痛。
2024年2月28日，Tonix Pharmicals Holding Corp. 宣布成功完成其 TNX-1500 的1期临床阶段，该试验是器官移植排斥反应和自身免疫性疾病的潜在治疗方法。该试验涉及在健康志愿者中对一种 FC 修饰的人源化抗 CD40L 单克隆抗体 TNX-1500 的单一剂量递增研究。该试验的结果预计将在2024年第三季度公布。该公司首席执行官塞思·莱德曼强调了 TNX-1500 有可能提高移植耐受性，降低与第一代抗CD40L单克隆抗体相关的血栓形成风险。专注于开发中枢神经系统疾病和免疫学疗法的Tonix Pharmicals还计划进行一项预防肾脏移植排斥反应的2期试验。该公司的目标是在2024年下半年提交另一候选药物Tonmya的新药申请，用于治疗纤维肌痛。
有用
没用